{
  "id": 17421006,
  "title": "Regeneron: 3 Key Takeaways for Long-Term Investors",
  "url": "https://urgent.news/2026/10/31/regeneron-3-key-takeaways-for-long-term-investors",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-31T14:49:48.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/earnings/takeaways/2026/10/31/regeneron-3-key-takeaways-for-long-term-investors/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Regeneron posted strong third quarter results for 2026, with total revenue increasing by 36% year-over-year to reach $5.1 billion. The company's success can be attributed to a combination of expanding commercial blockbusters and a proprietary genetics discovery engine that enables durable cash flow. Three key takeaways from the earnings call highlight the primary drivers of long-term value creation for long-term investors.\n\nFirstly, Dupixent, an injectable biologic drug targeting inflammatory pathways, reached record sales, with Sanofi's global net sales hitting $6.5 billion in the third quarter, marking a 35% year-over-year increase. This is particularly impressive considering the drug has been on the market for nearly a decade.\n\nSecondly, EYLEA HD, a high-dose injectable treatment for retinal eye diseases, saw its sales expand rapidly, despite facing increasing competition. In the U.S., third-quarter net sales amounted to $699 million, representing a remarkable 62% year-over-year growth. This growth demonstrates strong physician unit demand, which increased by 20% from the previous quarter.\n\nLastly, early clinical trials of an siRNA gene-silencing therapy designed to target CIDEB for nonalcoholic steatohepatitis, a metabolic liver disease, yielded promising results. In a preliminary study involving 40 participants, a single dose of the therapy led to a significant reduction in liver fat, averaging around 70% compared to baseline levels within just 12 weeks. This reduction brought mean liver fat to near or below the upper limit of normal at every tested dose level.\n\nRegeneron's commercial infrastructure is already established in major medical specialties, positioning the company to launch new pipeline candidates with reduced commercial building costs. The company anticipates increasing research spending by double-digits in 2027 to fund 15 late-stage clinical trials. With a diverse and compelling pipeline that has the potential to transform medicine across various diseases with significant unmet needs, Regeneron is well-positioned for long-term value creation.",
  "summary": "An early-stage liver disease therapy cut fat by 70% in just 12 weeks, signaling the genetics engine's potential to fuel growth beyond current blockbusters.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Regeneron: 3 Key Takeaways for Long-Term Investors",
        "url": "https://urgent.news/2026/10/31/regeneron-3-key-takeaways-for-long-term-investors-17422120",
        "published": "2026-10-31T15:09:48.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}